Skip to main content
SpringerLink
Log in

How to Manage Cystic Tumors of the Pancreas in High-Risk Individuals

  • Chapter
  • First Online:
Cystic Tumors of the Pancreas

  • 1068 Accesses

Abstract

Cystic tumors of the pancreas are detected with increasing frequency. Reliable differentiation between benign cysts, cysts with malignant potential, and cysts that harbor invasive cancer is crucial for patient management, but poses a clinical challenge. Interestingly, in individuals with an increased risk for pancreatic cancer, the prevalence of pancreatic cysts is high, up to 42 %. Cyst management in these high-risk individuals presents an even greater challenge, as little is known about the natural behavior of cystic lesions in general, but even less in this high-risk group.

Two groups with a hereditary risk for pancreatic cancer are recognized: individuals with a cancer-prone gene mutation and those without, but who have a strong family history of pancreatic cancer. The Cancer of the Pancreas Screening (CAPS) Consortium recommends screening individuals with an estimated tenfold increased risk on developing pancreatic cancer. Their guidelines recommend annual endoscopic ultrasonography and MRI/MRCP. Preliminary studies show an overall diagnostic yield of 9 %, but data on the long-term outcome of this surveillance strategy are still lacking. For the management of cystic tumors of the pancreas, the revised Sendai criteria are generally applied, recommending regular follow-up by EUS or MRI.

This chapter provides an overview of the current knowledge on cystic tumors of the pancreas in individuals with a hereditary risk for developing pancreatic cancer and discusses cyst management in these high-risk individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brugge WR, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126(5):1330–6.

    Article  PubMed  Google Scholar 

  2. Lee KS, et al. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol. 2010;105(9):2079–84.

    Article  PubMed  Google Scholar 

  3. Fernandez-del Castillo C, et al. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138(4):427–3; discussion 433–4.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Winter JM, et al. Periampullary and pancreatic incidentaloma: a single institution’s experience with an increasingly common diagnosis. Ann Surg. 2006;243(5):673–80; discussion 680–3.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Matthaei H, et al. Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2011;8(3):141–50.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Maitra A, et al. Precursors to invasive pancreatic cancer. Adv Anat Pathol. 2005;12(2):81–91.

    Article  PubMed  Google Scholar 

  7. Hruban RH, Wilentz RE, Maitra A. Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol Med. 2005;103:1–13.

    PubMed  Google Scholar 

  8. Schmidt CM, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg. 2007;246(4):644–51; discussion 651–4.

    Article  PubMed  Google Scholar 

  9. Sohn TA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239(6):788–97; discussion 797–9.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Iacobuzio-Donahue CA, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol. 2000;157(3):755–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sahin F, et al. Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol. 2003;16(7):686–91.

    Article  PubMed  Google Scholar 

  12. Schonleben F, et al. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg. 2008;393(3):289–96.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Crippa S, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol. 2010;8(2):213–9.

    Article  PubMed  Google Scholar 

  14. Jimenez RE, et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg. 1999;230(4):501–9; discussion 509–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kim SG, et al. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod Pathol. 2003;16(11):1086–94.

    Article  PubMed  Google Scholar 

  16. Salvia R, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239(5):678–85; discussion 685–7.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sarr MG, et al. Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? Ann Surg. 2000;231(2):205–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yachida S, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gandini S, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122(1):155–64.

    Article  CAS  PubMed  Google Scholar 

  20. Vrieling A, et al. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;126(10):2394–403.

    CAS  PubMed  Google Scholar 

  21. Tramacere I, et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer. 2010;126(6):1474–86.

    CAS  PubMed  Google Scholar 

  22. Huxley R, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007;96(3):507–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gapstur SM, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283(19):2552–8.

    Article  CAS  PubMed  Google Scholar 

  25. Li D, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301(24):2553–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Dat NM, Sontag SJ. Pancreatic carcinoma in brothers. Ann Intern Med. 1982;97(2):282.

    Article  CAS  PubMed  Google Scholar 

  27. Friedman JM, Fialkow PJ. Familial carcinoma of the pancreas. Clin Genet. 1976;9(5):463–9.

    Article  CAS  PubMed  Google Scholar 

  28. Ehrenthal D, et al. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer. 1987;59(9):1661–4.

    Article  CAS  PubMed  Google Scholar 

  29. Lynch HT, Fusaro L, Lynch JF. Familial pancreatic cancer: a family study. Pancreas. 1992;7(5):511–5.

    Article  CAS  PubMed  Google Scholar 

  30. Lynch HT, et al. Familial pancreatic cancer: a review. Semin Oncol. 1996;23(2):251–75.

    CAS  PubMed  Google Scholar 

  31. Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer. 2009;8(2):109–17.

    Article  PubMed  Google Scholar 

  32. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009;133(3):365–74.

    PubMed  Google Scholar 

  33. Iqbal J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. van Asperen CJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42(9):711–9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Goggins M, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56(23):5360–4.

    CAS  PubMed  Google Scholar 

  36. Lucas AL, et al. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts. Cancer. 2014;120(13):1960–7.

    Article  CAS  PubMed  Google Scholar 

  37. Mocci E, et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev. 2013;22(5):803–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Harinck F, et al. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet. 2012;20(5):577–9.

    Article  CAS  PubMed  Google Scholar 

  39. Jones S, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324(5924):217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Tischkowitz MD, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009;137(3):1183–6.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lynch HT, Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas. 1991;6(2):127–31.

    Article  CAS  PubMed  Google Scholar 

  42. de Snoo FA, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008;14(21):7151–7.

    Article  PubMed  Google Scholar 

  43. Rebours V, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008;103(1):111–9.

    Article  PubMed  Google Scholar 

  44. Korsse SE, et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet. 2013;50(1):59–64.

    Article  CAS  PubMed  Google Scholar 

  45. Giardiello FM, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.

    Article  CAS  PubMed  Google Scholar 

  46. Giardiello FM, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut. 1993;34(10):1394–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ruijs MW, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010;47(6):421–8.

    Article  CAS  PubMed  Google Scholar 

  48. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16):1790–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Klein AP, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634–8.

    Article  CAS  PubMed  Google Scholar 

  50. Brune KA, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010;102(2):119–26.

    Article  PubMed  PubMed Central  Google Scholar 

  51. McFaul CD, et al. Anticipation in familial pancreatic cancer. Gut. 2006;55(2):252–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Laffan TA, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008;191(3):802–7.

    Article  PubMed  PubMed Central  Google Scholar 

  53. de Jong K, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol. 2010;8(9):806–11.

    Article  PubMed  Google Scholar 

  54. Canto MI, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2(7):606–21.

    Article  PubMed  Google Scholar 

  55. Canto MI, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4(6):766–81.

    Article  PubMed  Google Scholar 

  56. Kluijt I, et al. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance. J Clin Gastroenterol. 2009;43(9):853–7.

    Article  PubMed  Google Scholar 

  57. Poley JW, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104(9):2175–81.

    Article  CAS  PubMed  Google Scholar 

  58. Verna EC, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010;16(20):5028–37.

    Article  PubMed  Google Scholar 

  59. Ludwig E, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106(5):946–54.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Vasen HF, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology. 2011;140(3):850–6.

    Article  CAS  PubMed  Google Scholar 

  61. Schneider R, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer. 2011;10(2):323–30.

    Article  PubMed  Google Scholar 

  62. Al-Sukhni W, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg. 2012;16(4):771–83.

    Article  PubMed  Google Scholar 

  63. Canto MI, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796–804; quiz e14-5.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Potjer TP, et al. Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res. 2013;19(2):442–9.

    Article  PubMed  Google Scholar 

  65. Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.

    Article  PubMed  Google Scholar 

  66. Brentnall TA, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131(4):247–55.

    Article  CAS  PubMed  Google Scholar 

  67. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology. 2001;1(5):477–85.

    Article  CAS  PubMed  Google Scholar 

  68. Kimmey MB, et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 2002;56(4 Suppl):S82–6.

    Article  PubMed  Google Scholar 

  69. Langer P, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009;58(10):1410–8.

    Article  CAS  PubMed  Google Scholar 

  70. Tanaka M, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.

    Article  PubMed  Google Scholar 

  71. Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol. 2007;102(10):2339–49.

    Article  PubMed  Google Scholar 

  72. Bartsch DK, et al. Multiple small “imaging” branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer. 2013;12(1):89–96.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

    Ingrid C. A. W. Konings MD, Djuna L. Cahen MD, PhD & Marco J. Bruno MD, PhD

Authors
  1. Ingrid C. A. W. Konings MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Djuna L. Cahen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco J. Bruno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingrid C. A. W. Konings MD .

Editor information

Editors and Affiliations

  1. Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC) Karolinska Institute at Center for Digestive Diseases Karolinska University Hospital, Stockholm, Sweden

    Marco Del Chiaro

  2. Center for Digestive Diseases Karolinska University Hospital, Stockholm, Sweden

    Stephan L. Haas

  3. Department of Surgery, University of Colorado at Denver Aurora, Colorado, USA

    Richard D. Schulick

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Konings, I.C.A.W., Cahen, D.L., Bruno, M.J. (2016). How to Manage Cystic Tumors of the Pancreas in High-Risk Individuals. In: Del Chiaro, M., Haas, S., Schulick, R. (eds) Cystic Tumors of the Pancreas. Springer, Cham. https://doi.org/10.1007/978-3-319-31882-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31882-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-31880-6

  • Online ISBN: 978-3-319-31882-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation